MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
| Miracle Applications Corp (NASDAQ: MIRA) | Delayed: 0.68 +0.03 (4.62%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.65 | 52 Week High | $0.04 | |||
| Open | $0.67 | 52 Week Low | $0.00 | |||
| Day High | $0.69 | P/E | N/A | |||
| Day Low | $0.67 | EPS | $0.00 | |||
| Volume | 128,683 | |||||
